UroGen Pharma Ltd. (URGN) Stock Score, Valuation & Financial Research
UroGen Pharma Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for URGN
UroGen Pharma Ltd. currently has a Wall Street Score of 24/100. The stored market price is $42.31. Its financial score is 15/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What UroGen Pharma Ltd. does
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and
URGN financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $42.31
- Market capitalization:
- $2.06B
- Revenue:
- $140.5M
- Net income:
- $-133.2M
- Free cash flow:
- $-162.7M
- Cash:
- $111.3M
- Total debt:
- $197.1M
- EPS:
- -3.19
- Financial score:
- 15/100
- Valuation score:
- 0/100
- Revenue score:
- 32/100
What stands out
- Reported year-over-year revenue growth is +0.3%.
- Free cash flow is $-162.7M, showing cash burn in the current stored period.
- The balance sheet shows $111.3M of cash versus $197.1M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 15/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research URGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.